recent
singlestrand
neg
sens
rna
virus
ssnsv
one
import
human
viral
pathogen
could
creat
cdna
inabl
manipul
genom
hinder
detail
genet
analysi
key
paper
conzelmann
laboratori
chang
public
method
recov
rabi
viru
rabv
cdna
discoveri
dramat
chang
broader
field
ssnsv
biolog
also
open
whole
new
avenu
studi
rabv
pathogen
develop
novel
rabv
vaccin
well
new
gener
rabvbas
vaccin
vector
creat
research
tool
import
neurosci
neuron
trace
neurotrop
virus
becom
invalu
tool
neuroscientist
quest
elucid
architectur
neuron
network
callaway
taber
et
al
ugolini
ugolini
compar
convent
method
neurotrac
virus
offer
advantag
selfamplif
ensur
equal
strong
label
cell
viru
pass
one
neuron
next
addit
viral
tracer
allow
specif
target
cell
type
although
numer
neurotrop
virus
known
mostli
rabi
viru
rabv
sever
member
alphaherpesviru
famili
employ
neuron
tracer
studi
date
rabv
particularli
suit
purpos
transport
strictli
transsynapt
way
littl
spread
nonneuron
cell
least
earli
time
infect
addit
rabv
exhibit
except
low
cytopathogen
infect
neuron
respect
rabv
par
even
superior
alphaherpesvirus
includ
prv
bharta
isol
rabv
howev
also
disadvantag
compar
herpesvirus
unlik
prv
rabv
pathogen
human
therefor
necessit
special
safeti
measur
also
rabv
rna
viru
strictli
cytoplasm
replic
cycl
permit
use
cell
typespecif
promot
limit
marker
gene
express
certain
cell
type
notwithstand
limit
rabv
gain
increas
popular
tool
neuron
circuit
analysi
present
overview
studi
employ
recombin
nonrecombin
rabv
neuron
tracer
highlight
technic
advanc
made
recent
year
earli
studi
rabv
spread
central
nervou
system
cn
util
fix
street
virus
differ
anim
model
mainli
studi
basi
differ
viral
pathogenesi
coulon
et
al
gillet
et
al
kucera
et
al
lafay
et
al
smart
charlton
tsiang
et
al
studi
clearli
show
strong
tropism
rabv
neuron
cell
also
reveal
differ
type
neuron
equal
infect
refract
infect
part
explain
strength
innerv
receptor
densiti
presynapt
membran
mark
differ
cell
tropism
observ
pathogen
attenu
mutant
strain
cv
also
pathogen
street
fix
virus
data
strongli
suggest
preferenti
use
differ
receptor
differ
rabv
strain
fact
sever
receptor
report
literatur
rel
import
unclear
coulon
et
al
jacotot
et
al
lentz
et
al
superti
et
al
thoulouz
et
al
tuffereau
et
al
whether
absenc
one
sever
receptor
certain
type
neuron
render
refract
infect
rabv
remain
determin
gener
suitabl
rabv
neuron
tracer
demonstr
sever
detail
timecours
studi
viral
spread
rodent
primat
model
astic
et
al
kelli
strick
ugolini
studi
note
except
low
cytotox
rabv
strict
timedepend
viral
spread
higher
order
neuron
limit
spread
nonneuron
cell
kelli
strick
also
carri
rigor
comparison
differ
rabv
strain
reveal
signific
differ
kinet
viral
spread
pioneer
work
carri
ugolini
kelli
laid
groundwork
larg
number
similar
studi
mostli
employ
alon
combin
convent
tracer
elucid
architectur
differ
neural
circuit
monkey
rat
guinea
pig
cat
buttnerennev
et
al
clower
et
al
graf
et
al
hashimoto
et
al
hoshi
et
al
iwata
et
al
strick
loi
et
al
morcuend
et
al
nassi
callaway
prevosto
et
al
rathelot
strick
rice
et
al
rice
et
al
ugolini
et
al
viemari
et
al
b
low
cytopathogen
neuron
clockworklik
kinet
viral
spread
hallmark
made
rabv
wide
use
neurotrac
howev
least
one
studi
highlight
variabl
paramet
ruigrok
et
al
reason
variabl
clear
genet
variabl
outbr
anim
differ
earli
innat
tindepend
humor
immun
respons
among
individu
anim
could
play
role
also
forgotten
rabv
inher
higher
spontan
mutat
rate
genet
variabl
dna
virus
abil
form
defect
interf
particl
passag
high
multipl
infect
moi
could
easili
result
phenotyp
chang
origin
viru
isol
depend
passag
histori
particular
viru
stock
use
probabl
possibl
complet
elimin
tempor
dispers
viral
spread
particularli
viru
spread
higher
order
neuron
gener
advis
use
infecti
dose
high
possibl
synchron
time
infect
therefor
increas
reproduc
attenu
strain
rabv
less
suitabl
neuron
tracer
studi
requir
spread
rabv
peripher
nerv
end
higher
order
neuron
cn
proven
quit
use
differ
kind
neuron
tracer
approach
aim
limit
viral
spread
monosynapt
connect
neuron
larsen
et
al
wickersham
et
al
b
achiev
delet
glycoprotein
g
gene
recombin
clone
strain
addit
viru
engin
express
gfp
delet
rabv
g
prevent
spread
viru
beyond
initi
infect
cell
insert
gfp
gene
ensur
strong
label
cell
bodi
dendrit
axon
obviat
need
histochem
stain
method
outlin
infect
neuron
wickersham
et
al
essenc
method
prevent
transsynapt
spread
limit
label
firstord
neuron
wickersham
wall
took
approach
devis
ingeni
strategi
target
initi
infect
cellspecif
manner
limit
viral
spread
monosynapt
connect
neuron
cell
specif
achiev
pseudotyp
rabv
avian
viru
glycoprotein
transfect
target
neuron
express
plasmid
avian
receptor
protein
tva
accomplish
monosynapt
spread
target
cell
also
receiv
express
plasmid
encod
rabv
g
valid
approach
first
demonstr
ex
vivo
brain
slice
transfect
transcompl
express
plasmid
improv
cellspecif
target
recombin
aav
helper
viru
use
express
rabv
g
tva
credepend
manner
open
whole
new
avenu
target
rabv
infect
select
cell
type
util
creexpress
transgen
mice
wall
et
al
strategi
hold
great
promis
label
monosynapt
circuit
mous
model
unfortun
genom
engin
approach
applic
small
mammal
genom
engin
primat
impract
due
long
gestat
period
high
reproduct
age
viral
genom
engin
also
instrument
first
studi
employ
two
differ
rabv
dual
trace
experi
ohara
impart
neuroinvas
stronger
neurotrop
onto
attenu
strain
rabv
g
gene
cv
use
replac
cognat
g
gene
hepfluri
strain
betagalactosidas
bgal
gfp
insert
nucleoprotein
n
phosphoprotein
p
gene
gener
two
differ
marker
virus
util
detect
neuron
project
two
separ
region
rat
brain
anoth
eleg
studi
util
monosynapt
restrict
gdelet
virus
develop
callaway
laboratori
doubl
label
premotor
spinal
interneuron
bilater
inject
two
differ
marker
virus
quadricep
muscl
newborn
mice
stepien
et
al
studi
littl
neurodegener
observ
infect
neuron
day
postinfect
interestingli
author
also
note
effici
infect
declin
dramat
mice
older
day
earli
pioneer
neuron
tracer
studi
rabv
util
nonrecombin
fix
laboratori
strain
futur
rabv
neuron
tracer
clearli
lie
use
recombin
clone
sever
factor
consid
endeavor
four
main
featur
qualifi
rabv
neuron
tracer
studi
strong
neurotrop
low
cytopathogen
abil
invad
cn
peripheri
wide
host
rang
neurotrop
rabv
larg
determin
glycoprotein
receptor
specif
morimoto
et
al
fact
rabi
appear
util
differ
cellular
receptor
mark
differ
viral
spread
differ
viral
strain
suggest
specif
neuron
label
modifi
extent
construct
recombin
rabv
express
differ
glycoprotein
gene
expect
kind
approach
receiv
signific
boost
threedimension
structur
rabv
g
elucid
main
featur
render
rabv
suitabl
neuron
tracer
studi
neuroinvas
multigen
trait
sole
determin
rabv
g
faber
et
al
shimizu
et
al
yamada
et
al
although
glycoprotein
highli
pathogen
viru
impart
neuroinvas
onto
attenu
strain
ohara
et
al
tan
et
al
multigen
natur
neuroinvas
impli
recombin
virus
util
differ
viral
backbon
differ
markedli
kinet
extent
viral
spread
glycoprotein
also
play
import
role
cytopathogen
differ
rabv
plenti
evid
direct
relationship
rabv
g
express
level
cytopathogen
note
highli
pathogen
cv
strain
consider
less
cytopath
attenu
strain
morimoto
et
al
cytopathogen
obviou
reason
littl
concern
gdelet
virus
might
becom
issu
foreign
glycoprotein
potenti
proapoptot
protein
use
replac
rabv
glycoprotein
respect
host
rang
need
kept
mind
differ
anim
vari
suscept
differ
rabv
strain
cv
strain
success
use
differ
anim
particularli
suit
rodent
model
develop
serial
passag
mous
brain
rabv
readili
amen
genet
manipul
insert
addit
transcript
unit
due
modular
natur
genom
ampli
exploit
express
foreign
antigen
marker
gene
like
gfp
betagalactosidas
foreign
gene
kb
success
insert
rabv
genom
mcgettigan
et
al
maximum
code
capac
rabv
like
consider
higher
structur
viral
particl
appear
pose
signific
constraint
size
foreign
gene
addit
transcript
cassett
place
differ
posit
affect
genom
replic
viral
fit
vari
degre
insert
n
p
exampl
inhibit
viral
replic
larger
extent
insert
g
l
rabv
toler
insert
addit
transcript
cassett
upstream
n
gene
posit
foreign
gene
also
affect
express
level
sinc
gradual
decreas
transcript
level
n
l
gene
purpos
neuron
tracer
studi
probabl
best
insert
addit
gene
downstream
posit
exhibit
less
inhibit
effect
replic
studi
recombin
variant
wirblich
schnell
character
lower
transcript
level
attenu
viral
strain
show
marker
gene
place
g
l
suffici
amplifi
readili
detect
neuron
cell
wirblich
schnell
unpublish
case
effect
gene
insert
viral
replic
assess
detail
timecours
experi
viru
particularli
case
virus
employ
dual
trace
experi
window
success
superinfect
neuron
two
differ
virus
potenti
rather
short
ohara
et
al
b
technolog
construct
recov
recombin
rabv
still
essenti
origin
report
schnell
et
al
notabl
improv
includ
use
hammerhead
ribozym
gener
exact
end
antigenom
rna
use
cmv
promot
drive
express
antigenom
rna
inou
et
al
le
mercier
et
al
recoveri
perform
differ
cell
line
mous
neuroblastoma
cell
appear
particularli
well
suit
purpos
easili
transfect
permiss
neurotrop
strain
babi
hamster
kidney
bhk
cell
number
infecti
fulllength
clone
avail
includ
two
clone
bat
rabv
strain
faber
et
al
orbanz
fink
sever
clone
fix
attenu
virus
huang
et
al
inou
et
al
ito
et
al
schnell
et
al
infecti
clone
pathogen
nishigahara
strain
wirblich
schnell
yamada
et
al
latter
prove
particularli
valuabl
neuron
tracer
studi
one
neurotrop
neuroinvas
strain
avail
one
least
cytopath
world
health
report
estim
rabv
transmit
infect
anim
caus
estim
human
death
annual
one
major
goal
treatment
control
rabv
infect
focus
vaccin
develop
first
record
vaccin
rabv
attenu
form
administ
pasteur
sinc
field
accumul
research
better
understand
pathogen
rabv
immun
biolog
potenti
host
rabi
diseas
affect
human
worldwid
viral
life
cycl
depend
reservoir
mammal
dietzschold
et
al
schnell
et
al
domest
wildlif
anim
dog
raccoon
skunk
mongoos
fox
bat
maintain
rabv
cycl
rosevear
et
al
schnell
et
al
therefor
vaccin
research
also
target
group
indirectli
protect
human
fatal
diseas
current
whole
kill
deactiv
rabv
virion
use
preand
postexposur
treatment
rabv
human
domest
anim
review
see
mcgettigan
safe
kill
rabv
vaccin
avail
replicationcompet
rabv
vaccin
consid
human
use
mcgettigan
howev
situat
differ
use
anim
especi
vaccin
wildlif
kill
viru
administ
bait
wild
wander
anim
would
ineffect
howev
oral
administ
liveattenu
form
rabv
era
use
wide
wildlif
million
dose
success
nearli
eradi
rabv
western
europ
anonym
grimm
despit
proven
efficaci
replicationcompet
virus
retain
risk
revert
caus
diseas
faber
et
al
research
focus
improv
safeti
vaccin
even
compromis
efficaci
see
led
develop
novel
vaccin
rabi
wildlif
success
live
rabv
vaccin
regimen
erad
rabi
western
europ
indic
promis
approach
residu
pathogen
vaccin
underli
need
improv
rabv
vector
revers
genet
technolog
rabv
provid
field
new
tool
manipul
genom
rabv
therefor
improv
safeti
efficaci
rabv
vaccin
dietzschold
et
al
faber
et
al
mcgettigan
et
al
morimoto
et
al
pulmanausahakul
et
al
schnell
et
al
effort
includ
sitedirect
mutagenesi
viral
gene
insert
proapoptot
antivir
gene
express
inflammatori
cytokin
chemokin
well
gene
delet
duplic
glycoprotein
gene
cenna
et
al
etessami
et
al
faber
et
al
faber
et
al
gomm
et
al
ito
et
al
kuang
et
al
morimoto
et
al
pulmanausahakul
et
al
shoji
et
al
wen
et
al
wirblich
et
al
zhao
et
al
zhao
et
al
rabv
g
often
target
attempt
attenu
due
known
role
viral
pathogen
rabv
g
believ
main
determin
viral
pathogen
determin
viral
tropism
review
see
dietzschold
et
al
schnell
et
al
due
fact
g
primari
target
virusneutr
antibodi
vna
prohibit
celltocel
spread
dietzschold
et
al
pulmanausahakul
et
al
despit
gener
success
convent
modifi
live
virus
use
immun
rabv
vaccin
immunogen
skunk
dog
custom
rabv
vaccin
construct
express
g
differ
fix
street
strain
rabv
construct
test
maximum
protect
mice
achiev
vaccin
rabv
express
ident
rabv
g
stem
find
gave
credenc
vaccin
design
custom
made
group
wildlif
respond
mainstream
vaccin
sever
differ
factor
employ
increas
immunogen
rabv
vaccin
enhanc
apoptosi
overexpress
apoptot
gene
shown
improv
rabv
immunogen
faber
et
al
rabv
modifi
overexpress
cytochrom
c
show
increas
apoptosi
primari
neuron
mark
reduct
mortal
administ
intranas
mous
surviv
direct
correl
induct
vna
fact
compar
control
rabv
express
cytochrom
c
effect
dose
lower
control
vastli
improv
vaccin
vector
pulmanausahakul
et
al
express
multipl
copi
rabv
g
led
enhanc
immunogen
viral
attenu
neuron
cell
line
primari
neuron
infect
rabv
express
multipl
g
protein
show
evid
increas
apoptosi
faber
et
al
immunogen
studi
construct
result
higher
antibodi
titer
rabv
g
rabv
n
insert
tripl
rabv
g
shown
attenu
vaccin
construct
render
viru
complet
apathogen
inject
directli
brain
immunocompromis
immunesuffici
mice
faber
et
al
rabv
express
tripl
g
protect
mice
intracrani
ic
challeng
lethal
rabv
infect
kill
unvaccin
mice
immun
analysi
show
induct
high
vna
titer
mice
day
postimmun
postexposur
immun
rabv
express
tripl
g
administ
intracrani
prevent
lethal
rabi
enceph
note
mechan
viral
attenu
secondari
express
multipl
g
complet
understood
present
data
rabv
express
tripl
g
actual
show
g
protein
level
less
tripl
g
construct
compar
control
rabv
h
howev
effect
g
protein
express
level
pathogen
control
viru
encod
three
g
gene
one
function
start
codon
nearli
pathogen
construct
contain
one
g
note
higher
g
express
level
inde
respons
observ
rabv
attenu
codon
optim
wirblich
schnell
might
better
approach
increas
g
level
base
fact
singl
point
mutat
delet
start
codon
one
two
g
would
result
viru
similar
pathogen
parent
viru
faber
et
al
howev
caution
advis
strategi
base
sole
chang
express
level
rabv
g
protein
chang
codon
usag
result
chang
g
express
level
suffic
render
pathogen
rabv
apathogen
wirblich
schnell
anoth
practic
way
improv
live
rabv
construct
introduct
specif
mutat
includ
abolish
neurotrop
rabv
dietzschold
et
al
mention
rabv
g
determin
tropism
viru
albeit
spectrum
specif
receptor
absolut
necessari
infect
remain
elus
mutat
rabv
g
posit
replac
arginin
glutam
acid
attenu
viru
upon
ic
administr
mcgettigan
et
al
addit
random
mutat
occur
posit
g
exchang
asparagin
lysin
increas
pathogen
attenu
rabv
construct
contain
mutat
faber
et
al
random
mutat
provid
anoth
residu
excel
target
attenu
rabv
vaccin
construct
faber
et
al
altern
approach
test
mebats
et
al
show
delet
conserv
dynein
light
chain
bind
motif
rabv
p
combin
rabv
g
mutat
attenu
rabv
compar
rabv
administ
suckl
mice
mebats
tan
et
al
confirm
find
show
delet
motif
rabv
p
affect
primari
transcript
rabv
find
issu
custom
made
vaccin
abil
use
mutat
conjunct
mutat
specif
strain
viru
could
use
improv
safeti
profil
vaccin
sitedirect
mutagenesi
excel
method
base
limit
number
mutat
singl
dual
nucleotid
compar
wildtyp
rabv
g
therefor
revert
possibl
anoth
approach
taken
advantag
immun
compon
express
cytokin
chemokin
hematopoiet
factor
increas
immunogen
decreas
pathogen
tumor
necrosi
factoralpha
macrophag
inflammatori
protein
granulocyt
macrophag
cell
stimul
factor
rant
express
rabv
vector
pathogen
immunogen
follow
modern
intrigu
approach
shown
increas
immunogen
manipul
arm
innat
adapt
immun
system
faber
et
al
zhao
et
al
zhao
et
al
nevertheless
also
rais
concern
applic
cytokineschemokin
speci
specif
risk
use
human
anim
larg
unknown
includ
toxic
potenti
trigger
autoimmun
rabv
overexpress
rant
exampl
shown
increas
pathogen
rabv
due
excess
inflammatori
cell
cn
addit
concern
indic
express
multipl
copi
g
exist
exchang
one
nucleotid
within
atg
start
codon
insert
gene
would
revert
recombin
rabv
wildtyp
rabv
summari
mani
advanc
vastli
improv
safeti
profil
immunogen
rabv
vaccin
addit
inform
gather
interact
rabv
host
bettertailor
vaccin
design
vaccin
great
impact
human
health
continu
mainstay
prevent
treatment
diseas
scientif
research
improv
understand
interact
vaccin
immun
system
differ
type
vaccin
strategi
avail
viral
vector
manipul
year
prove
efficaci
induct
humor
cellular
immun
respons
review
focus
exclus
rabvbas
vaccin
vector
note
sever
import
characterist
render
rabv
favor
vaccin
deliveri
platform
viru
recoveri
conduct
revers
genet
system
use
cdna
copi
rabv
antigenom
rabv
rel
simpl
genom
organ
permit
easi
manipul
cdna
tradit
clone
techniqu
foreign
gene
vaccin
antigen
target
stabli
incorpor
genom
stabil
foreign
nonessenti
gene
exemplifi
express
bacteri
chloramphenicol
acetyltransferas
cat
gene
insert
rabv
genom
recov
viru
serial
passag
cell
cultur
mebats
et
al
b
viral
vector
sustain
replic
capac
insert
multipl
larg
gene
instanc
infecti
viru
recov
insert
gagpol
precursor
env
gene
increas
genom
size
wild
type
mcgettigan
et
al
import
advantag
rabv
compar
viral
vector
adenoviru
preexist
rabv
seroposit
neglig
gener
popul
rabv
genet
phenotyp
similar
fellow
rhabdoviru
vesicular
stomat
viru
vsv
permit
exchang
ectodomain
rabv
glycoprotein
vsv
recombin
viru
effect
boost
preimmun
individu
part
vaccin
schedul
tan
et
al
last
attenu
rabv
vector
effect
decreas
pathogen
maintain
antigenspecif
immunogen
mcgettigan
et
al
critic
vectorspecif
pathogen
primari
concern
live
viru
vector
addit
use
less
pathogen
vaccin
strain
rabv
see
effect
molecular
attenu
techniqu
includ
gene
mutat
delet
insert
rearrang
mcgettigan
et
al
rabv
life
cycl
exclus
cytoplasm
recombin
integr
unlik
occur
vaccin
strain
rabv
use
develop
vaccin
deriv
attenu
sad
strain
use
oral
immun
fox
europ
sad
highli
attenu
success
passag
differ
cell
type
conzelmann
et
al
unlik
pathogen
rabv
strain
sad
limit
abil
invad
cn
peripher
inocul
site
conzelmann
et
al
limit
invas
cn
sad
posit
correl
immunogen
viru
perhap
inabl
sequest
cn
allow
rapidli
recogn
immun
system
benefici
vaccin
develop
rel
safe
highli
immunogen
administ
peripher
howev
even
sad
pathogen
administ
directli
brain
via
intranas
rout
mcgettigan
et
al
thu
addit
molecular
strategi
attenu
viru
develop
see
past
year
scientist
sought
develop
vaccin
human
immunodefici
goal
remain
unreal
although
correl
protect
still
uncertain
current
belief
field
effect
vaccin
candid
induc
arm
immun
humor
cellular
haut
ertl
studi
monkey
immun
liveattenu
simian
immunodefici
viru
siv
show
protect
wildtyp
strain
homolog
siv
koff
et
al
find
gave
credenc
construct
live
viral
vaccin
control
hiv
recent
year
sever
vaccin
vector
approach
capabl
elicit
type
immun
respons
dna
pox
adenoviru
vector
evalu
preclin
see
gomm
et
al
refer
within
rabv
one
vector
intracellular
life
cycl
abil
stabli
express
foreign
antigen
probabl
candid
hiv
vaccin
import
studi
conduct
show
immunogen
recombin
rabv
vector
anim
first
time
studi
rabv
engin
express
envelop
protein
either
laboratori
adapt
dualtrop
isol
recombin
viru
recov
bhk
cell
function
foreign
envelop
protein
confirm
fusion
assay
human
cell
line
immunogen
evalu
monitor
envelopespecif
antibodi
respons
mice
inocul
footpad
inject
left
either
unboost
boost
recombin
protein
boost
mice
seroconvert
recombin
viru
express
induc
neutral
antibodi
demonstr
rabv
effici
prime
b
cell
robust
humor
respons
subsequ
studi
show
prime
alon
vector
could
also
induc
cytotox
lymphocyt
ctl
crossreact
heterolog
envelop
protein
mcgettigan
et
al
togeth
studi
clearli
demonstr
potenti
rabv
vector
elicit
balanc
humor
cellular
immun
respons
evid
field
continu
promot
import
cellular
immun
respons
control
infect
rabvbas
vector
redesign
incorpor
structur
nonsurfac
protein
gag
pol
compar
highli
variabl
envelop
protein
gag
one
conserv
protein
fact
gag
epitop
conserv
among
differ
clade
found
individu
infect
suggest
import
viral
fit
durali
et
al
mcadam
et
al
rolland
et
al
perspect
vaccin
develop
gag
attract
vaccin
target
antigen
mcgettigan
et
al
gener
rabv
express
gag
electron
microscopi
studi
infect
hela
cell
show
virusencod
gag
protein
manifest
particl
bud
plasma
membran
cytoplasm
vacuol
previous
observ
express
virus
karacosta
et
al
vivo
immunogen
studi
demonstr
rabv
gag
vector
induc
gagspecif
cell
mhc
class
gagspecif
cell
receptor
ctl
activ
ifngsecret
mcgettigan
et
al
shown
rabv
vector
induc
humor
cellular
immun
respons
vivo
research
focu
return
vector
safeti
besid
efficaci
safeti
chief
concern
vaccin
develop
though
sad
strain
use
rabvbas
vector
substanti
decreas
vectorassoci
pathogen
addit
attenu
techniqu
employ
approach
rabv
vector
express
gag
engin
includ
either
mutat
delet
amino
acid
rabv
g
cytoplasm
domain
combin
mcgettigan
et
al
engin
virus
apathogen
follow
intracrani
challeng
mice
compar
parent
strain
moreov
gagspecif
cellular
immun
respons
decreas
chang
rabv
g
mcgettigan
et
al
immunogen
studi
encourag
mutat
introduc
test
rabv
vectorencod
gagpol
precursor
env
gene
note
vector
sustain
replic
capac
gagspecif
immunogen
increas
genom
size
wild
type
mcgettigan
et
al
vaccin
research
also
extend
identif
adjuv
improv
chang
phenotyp
immun
respons
one
deal
target
pathogen
hiv
vaccin
research
live
viral
vector
manipul
express
inflammatori
cytokin
time
viral
replic
way
enhanc
immun
respons
rabv
vaccin
studi
includ
ifnb
vaccin
adjuv
induc
respons
addit
stimul
prolifer
cell
b
cell
gener
stimul
respons
ifnb
howev
antiinflammatori
cytokin
thought
skew
respons
may
influenc
expans
cell
faul
et
al
rabv
vaccin
vector
coexpress
gag
env
either
murin
test
mice
highli
attenu
express
reduc
cellular
immun
respons
gag
env
significantli
improv
humor
respons
howev
reduc
cellular
immun
respons
significantli
improv
antienv
humor
immun
respons
recent
shown
rabv
express
gag
ifnb
less
pathogen
control
ifnb
express
result
lower
viral
replic
vivo
compar
control
even
lower
viral
replic
ifnb
express
seem
increas
percentag
activ
cell
primari
respons
faul
et
al
faul
et
al
novel
approach
vaccin
design
take
advantag
antigen
present
capac
dendrit
cell
dc
earlier
studi
shown
rabv
could
infect
matur
human
dc
express
proinflammatori
cytokin
via
activ
nfkb
pathway
foley
et
al
li
et
al
immun
mice
rabvinfect
dc
stimul
cellular
humor
immun
respons
mice
shown
rabvinfect
dc
contrast
inocul
rabvbas
vector
mckenna
et
al
tan
et
al
could
use
homolog
primeboost
approach
lead
increas
gagspecif
cellular
immun
respons
wanjalla
et
al
final
test
effect
novel
vaccin
construct
requir
model
protect
aidslik
infect
could
monitor
approach
rabv
backbon
plasmid
contain
mutat
whose
rabv
g
ectodomain
replac
vsv
use
construct
recombin
rabv
express
siv
env
gag
gagpol
protein
faul
et
al
b
mckenna
et
al
construct
allow
heterolog
primeboost
vaccin
regimen
approach
previous
shown
increas
cellular
respons
higher
primeonli
approach
tan
et
al
two
independ
monkey
studi
rhesu
macaqu
prime
boost
rabv
construct
siv
gag
siv
env
mckenna
et
al
siv
gagpol
siv
env
faul
et
al
b
mckenna
et
al
challeng
either
highli
pathogen
siv
respect
faul
et
al
b
mckenna
et
al
compar
vector
control
vaccin
group
seroconvert
induct
neutral
antibodi
cell
vaccin
protect
aidslik
diseas
specif
protect
highli
pathogen
siv
strain
combin
lack
vectorinduc
pathogen
indic
great
promis
rabvbas
vector
vaccin
hepat
c
viru
hcv
affect
million
peopl
worldwid
common
caus
liver
diseas
requir
transplant
adult
tellinghuisen
et
al
case
chronic
infect
develop
sever
liver
diseas
includ
cirrhosi
hepatocellular
carcinoma
major
obstacl
treatment
control
hcv
lie
errorpron
replic
machineri
increas
genet
variabl
hcv
within
individu
result
quasispeci
antivir
therapi
help
manag
diseas
howev
sever
disadvantag
includ
low
rate
respons
toxic
similar
hiv
correl
protect
hcv
well
understood
howev
appreci
need
induc
neutral
antibodi
nab
cell
multipl
hcv
antigen
howev
humor
respons
remain
larg
unknown
epitop
import
nab
target
lead
steril
immun
tellinghuisen
et
al
von
hahn
et
al
rabv
vaccin
construct
hcv
construct
test
mice
shown
induc
humor
cellular
respons
recombin
rabv
construct
express
chimer
contain
transmembran
rabv
g
cytoplasm
domain
shown
allow
cell
surfac
express
moreov
chimer
incorpor
rabv
virion
humor
studi
kill
rabv
particl
administ
mice
primeboost
regimen
shown
induc
detect
antibodi
boost
measur
elisa
mice
prime
live
rabv
construct
clone
express
hcv
envelop
protein
upon
express
interact
noncoval
heterodimer
complex
retain
er
shown
mount
cellular
immun
respons
capabl
lyse
cell
puls
hcvspecif
peptid
siler
et
al
global
impact
emerg
infecti
diseas
becom
topic
interest
vaccin
develop
research
faber
et
al
sever
acut
respiratori
syndrom
sar
one
diseas
whose
caus
agent
coronaviru
name
sarscov
vaccin
standpoint
sarscov
may
import
pathogen
despit
fast
declin
sar
report
case
due
exist
anim
reservoir
raccoon
dog
chines
ferret
badger
thought
antibodi
sarscov
spike
protein
neutral
therefor
potenti
target
vaccin
see
faber
et
al
refer
within
vaccin
studi
liveattenu
recombin
rabv
contain
mutat
express
sarscov
protein
shown
induc
high
neutral
antibodi
mice
faber
et
al
translat
studi
wildlif
reservoir
use
live
rabv
may
possibl
base
efficaci
live
rabv
vaccin
erad
rabv
reservoir
wildlif
safeti
major
concern
develop
vaccin
especi
live
replicationcompet
vaccin
consid
due
likelihood
revert
residu
vector
pathogen
sever
method
use
improv
safeti
rabv
vaccin
maintain
immunogen
see
wirblich
schnell
refer
within
despit
great
improv
replicationcompet
rabv
still
potenti
safeti
concern
associ
use
live
virus
widespread
immun
human
even
highli
attenu
rabv
lethal
follow
intracrani
inocul
least
immunodefici
host
order
address
safeti
concern
virus
attenu
complet
genom
delet
essenti
gene
render
vector
unabl
complet
viral
life
cycl
attenu
strategi
use
mani
viral
backbon
adenoviru
ad
vaccinia
viru
vv
canarypox
viru
cpv
herp
simplex
viru
hsv
vsv
rabv
bozac
et
al
cenna
et
al
cenna
et
al
coulibali
et
al
gomm
et
al
peng
et
al
publicov
et
al
russel
et
al
delet
rabv
gene
p
gener
replicationdefici
rabv
cenna
et
al
cenna
et
al
term
lack
viral
compon
requir
complet
viral
life
cycl
rabv
p
phosphoprotein
cofactor
viral
rna
polymeras
delet
sever
hinder
intracellular
replic
cenna
et
al
howev
due
role
assembl
bud
mdelet
viru
structur
impair
form
mainli
cellassoci
rodshap
particl
instead
typic
bulletshap
particl
also
role
regul
balanc
transcript
replic
mdelet
viru
may
impair
level
viral
replic
effect
virion
format
reduc
infecti
titer
much
mebats
et
al
addit
delet
p
may
addit
unknown
effect
viral
fit
contribut
immunogen
mcgettigan
et
al
gener
pdelet
replicationdefici
rabv
potenti
use
preor
postexposur
vaccin
regimen
prevent
human
rabi
infect
cenna
et
al
like
candid
would
induc
antibodi
potent
antivir
effector
function
current
regimen
use
inactiv
rabv
particl
requir
sever
dose
effect
headtohead
comparison
live
pdelet
rabv
inactiv
rabv
found
mice
immun
pdelet
greater
surviv
proportion
greater
respons
lethal
challeng
mice
immun
inactiv
viru
cenna
et
al
later
studi
show
mdelet
rabv
even
potent
pdelet
mice
induc
greater
igg
vna
titer
protect
lethal
challeng
mice
even
immun
titer
low
fociform
unit
cenna
et
al
notabl
neither
por
mdelet
viru
induc
clinic
sign
rabi
found
brain
spinal
cord
follow
intramuscular
inject
immunocompromis
knockout
mice
cenna
et
al
cenna
et
al
replic
impair
rabv
vector
lack
rabv
express
rabv
g
protein
shown
safe
immunogen
mice
nonhuman
primat
fact
mdelet
rabv
fourfold
higher
vna
titer
day
inocul
compar
commerci
avail
kill
rabv
vaccin
one
hundr
eighti
day
later
monkey
receiv
mdelet
rabv
maintain
higher
vna
titer
antibodi
shown
higher
avid
kill
hdcv
cenna
et
al
data
strongli
demonstr
potenti
replicationdefici
rabv
replac
current
preand
postexposur
rabv
vaccin
gdelet
rabv
term
singlecycl
spreaddefici
lack
viral
compon
requir
viral
spread
infect
rabv
g
critic
role
attach
entri
viru
host
cell
make
g
one
import
determin
viral
pathogen
dietzschold
et
al
pulmanausahakul
et
al
particl
lack
g
undergo
one
complet
cycl
intracellular
replic
produc
progeni
unabl
spread
mebats
et
al
b
shown
infect
singl
neuron
follow
intracrani
inocul
gdelet
rabv
etessami
et
al
wickersham
et
al
viru
particl
lack
g
still
capabl
bud
although
lower
effici
mebats
et
al
b
virion
howev
incap
attach
entri
secondari
host
cell
gomm
et
al
gener
gdelet
rabvencod
gag
develop
vaccin
compar
replicationcompet
parent
viru
gdelet
rabv
gener
lower
rabvspecif
antibodi
respons
equival
gagspecif
cell
respons
moreov
respons
enhanc
heterolog
boost
gdelet
rabv
complement
vsv
glycoprotein
show
singlecycl
rabv
promis
platform
safe
live
viral
vaccin
studi
analyz
similar
respons
induc
nonhuman
primat
simplic
plastic
rabv
genom
one
mani
advantag
vaccin
vector
genom
amen
inclus
whole
foreign
antigen
rabv
protein
chimera
rabv
g
n
protein
test
carrier
foreign
antigen
proven
immunogen
appli
live
kill
vaccin
koser
et
al
langley
et
al
smith
et
al
sever
possibl
advantag
use
rabv
protein
carrier
rabv
g
carrier
express
foreign
envelop
protein
combin
rabvcd
allow
insert
foreign
gene
rabv
virion
mebats
conzelmann
mebats
et
al
smith
et
al
ii
set
immunogen
epitop
may
present
organ
structur
may
increas
immunogen
iii
depend
carrier
rabv
n
foreign
antigen
form
chimera
could
stabil
antigen
allow
longer
express
impact
immunogen
koser
et
al
viabil
immunogen
rabv
construct
contain
g
n
fusion
protein
extens
studi
koser
et
al
siler
et
al
smith
et
al
rnp
obtain
recombin
rabv
construct
gfp
fuse
rabv
n
use
immun
mice
primeboost
regimen
comparison
control
immun
gfp
mice
immun
rnp
significantli
higher
antibodi
gfp
seem
depend
cell
respons
gfpspecif
antibodi
detect
deplet
cell
koser
et
al
rabv
g
protein
carrier
foreign
antigen
also
shown
efficaci
induc
immun
respons
mice
monkey
mckenna
et
al
mckenna
et
al
smith
et
al
vaccin
strategi
employ
substanti
humor
respons
known
good
correl
protect
rabv
g
chimera
carri
bacillu
anthraci
protect
antigen
pa
suffici
incorpor
pa
virion
live
kill
viral
particl
induc
antipa
antibodi
mice
detect
postprim
increas
boost
potenti
conflict
interest
j
consult
molecular
target
technolog
inc
inventor
coinventor
sever
patent
rabvbas
vaccin
vaccinebas
vector
